close

Clinical Trials

1 184 185 186 187 188 209
Number of results: 4174

Excel print is not allowed for data more than 300.Please search above for fewer data.

Date Product Disease Phase Company Therapeutic area
2012-06-11 Victoza® (liraglutide) type 2 diabetes observational study Novo Nordisk (Denmark) Metabolic diseases
2012-06-11 LY2605541 type 1 and 2 diabetes 2 Boehringer Ingelheim (Germany) - Eli Lilly (USA) Metabolic diseases
2012-06-09 albiglutide type 2 diabetes 3 GSK (UK) Metabolic diseases
2012-06-09 linagliptin (Tradjenta® in the US and Trajenta® in Europe) type 2 diabetes 3 Boehringer Ingelheim (Germany) - Eli Lilly (USA) Metabolic diseases
2012-06-09 empagliflozin (BI 10773) type 2 diabetes 2 Boehringer Ingelheim (Germany) - Eli Lilly (USA) Metabolic diseases
2012-06-09 insulin degludec type 2 diabetes 3a Novo Nordisk (Denmark) Metabolic diseases
2012-06-09 Bydureon® (exenatide)

type 2 diabetes

Alkermes (USA - Ireland) Amylin Pharmaceuticals (USA) Metabolic diseases
2012-06-09 Bydureon™ (exenatide)

type 2 diabetes

Alkermes (USA - Ireland) Amylin Pharmaceuticals (USA) Metabolic diseases
2012-06-08 FSH-GEX™ (glycooptimized follicle-stimulating hormone) in vitro fertilisation
FSH treatment of female infertility
2 Glycotope (Germany) Gynecology - Women's health
2012-06-06 RoACTEMRA®/ACTEMRA® outside Europe (tocilizumab) rheumatoid arthritis 4 Roche (Switzerland) Chugai (Japan) Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
2012-06-06 ACZ885 (canakinumab)

systemic juvenile idiopathic arthritis (SJIA)

3 Novartis (Switzerland) Autoimmune diseases - Rare diseases
2012-06-06 ACZ885 (canakinumab)

TNF Receptor-Associated Syndrome (TRAPS)

2 Novartis (Switzerland) Autoimmune diseases - Rare diseases
2012-06-06 Atu027

advanced solid tumours including neuroendocrine cancers and breast cancers

1 Silence Therapeutics (UK) Cancer - Oncology
2012-06-06 abediterol chronic obstructive pulmonary disease (COPD) 2 Almirall (Spain) Respiratory diseases
2012-06-06 catumaxomab (Removab®) malignant ascites due to epithelial cancer
3b Fresenius Biotech (Germany) Cancer - Oncology
2012-06-06 Afolia (Follicle Stimulating Hormone [r-FSH]) (biosimilar product) ovarian stimulation in patients undergoing assisted reproduction technology (ART) 3 Finox Biotech (Switzerland) Gynecology - Women's health
2012-06-05 masitinib Gleevec®-resistant gastrointestinal stromal tumors (GIST) 2 AB Science (France) Cancer Oncology
2012-06-05 TB-402 (Anti-Factor VIII)

prophylaxis of venous thromboembolism (VTE) after total hip surgery

2b BioInvent (Sweden) ThromboGenics (Belgium) Cardiovascular diseases
2012-06-04 regorafenib (BAY 73-4506)

metastatic and/or unresectable gastrointestinal stromal tumors (GIST) which has progressed after at least imatinib and sunitinib as prior treatments

3 Bayer Healthcare (Germany) Cancer - Oncology
2012-06-04 trametinib metastatic melanoma with BRAF V600 mutations 3 GSK (UK) Cancer - Oncology